Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Pediatrics
Published in: BMC Pediatrics 1/2019

Open Access 01-12-2019 | Colchicine | Research article

Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet’s disease in Taiwan

Authors: Ya-Chiao Hu, Yao-Hsu Yang, Yu-Tsan Lin, Li-Chieh Wang, Hsin-Hui Yu, Jyh-Hong Lee, Bor-Luen Chiang

Published in: BMC Pediatrics | Issue 1/2019

Login to get access

Abstract

Backgrounds

Behçet’s disease (BD) is a rare vasculitic disorder affecting all sizes of vessels. Among BD patients, 4 to 25% of patients with diagnosed age younger than 16 years old are defined as juvenile BD (JBD). This study aimed to evaluate the clinical manifestations and treatments of patients with JBD, with a particular focus on the effectiveness and safety of anti-tumor necrosis factor (TNF)-alpha therapy.

Methods

We retrospectively reviewed data of all patients diagnosed with JBD at age of 16 years or younger in a tertiary hospital in Taiwan. The clinical manifestations, laboratory data, treatments, disease courses, and clinical outcomes were evaluated. The effectiveness of anti-TNF-alpha therapy was measured based on changes in Behçet’s Disease Current Activity Form (BDCAF) scores, prednisolone dosages and the immunosuppression load scores.

Results

Fifty-five patients were included in the study. The median age at disease onset was 11 years. The most common clinical presentation was recurrent oral aphthous ulcers (100%), followed by genital ulceration (69.1%), skin lesions (36.4%), gastrointestinal symptoms (29.1%), ocular involvement (27.3%), and arthralgia (27.3%). Ninety-one percent of the patients fulfilled the International Criteria for Behçet’s Disease, and 36.4% met the Paediatric Behçet’s Disease criteria. The most frequently used medications were prednisolone (74.5%) and colchicine (54.5%). Six patients with refractory or severe JBD received anti-TNF-alpha therapy. These patients were diagnosed at a younger age compared with those who did not receive anti-TNF-alpha therapy (7.5 vs 13 years; P = 0.012), the BDCAF scores reduced significantly at the 1st month, the 6th month and 1 year after the treatment. They did not use steroids after the first year of treatment, and, after treatment for 6 months, their immunosuppression load scores reduced significantly. Due to the limited case numbers, literature reviews of anti-TNF-alpha therapy for refractory JBD were conducted, which had a total 18 JBD patients receiving anti-TNF-alpha therapy, of which fifteen patients had favorable outcomes after treatment with minimal side effects.

Conclusions

Anti-TNF-alpha therapy may be necessary for JBD patients with refractory disease courses. Anti-TNF-alpha therapy was effective and safe in these patients, especially regarding its corticosteroid- and immunosuppressive drug-sparing effects.
Literature
1.
2.
Greco A, et al. Behcet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567–75.CrossRefPubMed
3.
Krause I, et al. Childhood Behcet’s disease: clinical features and comparison with adult-onset disease. Rheumatology (Oxford). 1999;38(5):457–62.CrossRef
4.
Koné-Paut I, et al. Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016;75(6):958–64.CrossRefPubMed
5.
See LC, et al. Sex- and age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study. Semin Arthritis Rheum. 2013;43(3):381–6.CrossRefPubMed
6.
Karincaoglu Y, et al. Demographic and clinical properties of juvenile-onset Behcet’s disease: A controlled multicenter study. J Am Acad Dermatol. 2008;58(4):579–84.CrossRefPubMed
7.
Sungur GK, et al. Clinical and demographic evaluation of Behcet disease among different paediatric age groups. Br J Ophthalmol. 2009;93(1):83–7.CrossRefPubMed
8.
Hatemi G, et al. 2018 Update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis. 2018;77(6):808–18.PubMed
9.
Tanida S, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet’s disease. Clin Gastroenterol Hepatol. 2015;13(5):940–8 e3.CrossRefPubMed
10.
Vallet H, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.CrossRefPubMed
11.
12.
Calvo-Rio V, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223–31.CrossRef
13.
Inoue N, et al. Long-term safety and efficacy of adalimumab for intestinal Behcet's disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15(3):395–401.CrossRefPubMedPubMedCentral
14.
Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behcet's disease. Arthritis Rheum. 2003;49(4):599–600.CrossRefPubMed
15.
Kaneko U, et al. Two patients with childhood-onset Behcet's disease successfully treated by anti-tumor necrosis factor therapy. Nihon Rinsho Meneki Gakkai Kaishi. 2010;33(3):157–61.CrossRefPubMed
16.
Watanabe S, et al. A young girl with refractory intestinal Behcet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent. Rheumatol Int. 2013;33(12):3105–8.CrossRefPubMed
17.
Bhakta BB, et al. Behcet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38(8):728–33.CrossRef
18.
Nussenblatt RB, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology. 2005;112(5):764–70.CrossRefPubMed
19.
International Study Group for Behçet’s, D. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335(8697):1078–80.
20.
International Team for the Revision of the International Criteria for Behcet’s, D. The international criteria for Behcet's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.CrossRef
21.
Batu ED, et al. The performance of different classification criteria in paediatric Behcet’s disease. Clin Exp Rheumatol. 2017;35(Suppl 108(6)):119–23.PubMed
22.
23.
Gallizzi R, et al. A national cohort study on pediatric Behcet's disease: cross-sectional data from an Italian registry. Pediatr Rheumatol Online J. 2017;15(1):84.CrossRefPubMedPubMedCentral
24.
Chang YS, Yang YH, Chiang BL. Neonatal Behcet's disease without maternal history. Clin Rheumatol. 2011;30(12):1641–5.CrossRefPubMed
25.
Fain, O., et al., Neonatal Behçet’s disease. Vol. 98. 1995. 310–311.
26.
A Lewis, M. and B. L Priestley, Transient neonatal Behçet’s disease Vol. 61. 1986. 805–806.
27.
Thivolet, J., F. Cambazard, and M. F Genvo, [Maternally-transmitted severe neonatal aphthosis]. Vol. 109. 1982. 815–816.
28.
G Fam, A., et al., Neonatal Behcet’s Syndrome in an Infant of a Mother with the Disease Vol. 40. 1981. 509–512.
29.
Kone-Paut I, et al. Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford). 2011;50(1):184–8.CrossRef
30.
Matsumura K, Nakase H, Chiba T. Efficacy of oral tacrolimus on intestinal Behcet’s disease. Inflamm Bowel Dis. 2010;16(2):188–9.CrossRefPubMed
31.
Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009;22(3):557–65.CrossRefPubMed
32.
33.
Brinkman DMC, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology. 2013;52(9):1674–9.CrossRefPubMed
34.
Simonini G, et al. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev. 2010;9(10):674–83.CrossRefPubMed
35.
Robinson AB, Gallentine WB, Rabinovich CE. Pediatric neuro-Behcet’s disease responsive to adalimumab. Pediatr Neurol. 2010;43(4):291–3.CrossRefPubMed
36.
Cantarini L, et al. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int J Immunopathol Pharmacol. 2009;22(2):551–5.CrossRefPubMed
37.
Evereklioglu C, Borlu M. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-α. Br J Ophthalmol. 2008;92(8):1034.CrossRefPubMed
38.
Seyahi E, et al. Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behçet’s syndrome. Rheumatology. 2007;46(7):1213–4.CrossRefPubMed
39.
Sfikakis PP, et al. Brief report: drug-free long-term remission in severe Behcet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol. 2017;69(12):2380–5.CrossRefPubMed
40.
Caso F, et al. Refractory pemphigus foliaceus and Behcet’s disease successfully treated with tocilizumab. Immunol Res. 2013;56(2–3):390–7.CrossRefPubMed
41.
Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: report of two cases. Rheumatology (Oxford). 2013;52(10):1923–4.CrossRef
42.
Deroux A, Chiquet C, Bouillet L. Tocilizumab in severe and refractory Behcet’s disease: four cases and literature review. Semin Arthritis Rheum. 2016;45(6):733–7.CrossRefPubMed
Metadata
Title
Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet’s disease in Taiwan
Authors
Ya-Chiao Hu
Yao-Hsu Yang
Yu-Tsan Lin
Li-Chieh Wang
Hsin-Hui Yu
Jyh-Hong Lee
Bor-Luen Chiang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2019
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-019-1613-5

Other articles of this Issue 1/2019

BMC Pediatrics 1/2019 Go to the issue

Research article

Allometric scaling of aerobic fitness outputs in school-aged pubertal girls

Research article

The performance of the EMS triage (RETTS-p) and the agreement between the field assessment and final hospital diagnosis: a prospective observational study among children < 16 years

Research article

Adolescent-parent communication on sexual and reproductive health issues and its factors among secondary and preparatory school students in Hadiya Zone, Southern Ethiopia: institution based cross sectional study

Research article

Successful conservative treatment of intestinal perforation in VLBW and ELBW neonates: a single centre case series and review of the literature

Research article

Association of adverse childhood experiences and neurodevelopmental disorders in people with fetal alcohol spectrum disorders (FASD) and non-FASD controls

Research article

Comparison of NIV-NAVA and NCPAP in facilitating extubation for very preterm infants